“Disturbing” Proposed Patient Population Trips Up Sanofi’s Semuloparin Before ODAC
13:52 EDT 20 Jun 2012 | Elsevier Business Intelligence
FDA’s Oncologic Drugs Advisory Committee recommends by a 14-1 vote, with one abstention, that the agency not approve the low molecular weight heparin for a population of cancer patients that is too broadly defined.
Original Article: “Disturbing” Proposed Patient Population Trips Up Sanofi’s Semuloparin Before ODAC
More From BioPortfolio on "“Disturbing” Proposed Patient Population Trips Up Sanofi’s Semuloparin Before ODAC"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
